IL23A Recombinant Antibody: Reliable Source for Your Research Needs

The IL23A recombinant antibody from Alpha Lifetech Incorporation offers a powerful tool for researchers investigating immune responses and associated pathologies. IL23A, or Interleukin 23 A, plays a crucial role in promoting inflammation and is implicated in various autoimmune diseases, making this antibody essential for studies in immunology and therapeutic development, Crafted using advanced recombinant techniques, the IL23A antibody ensures high specificity and sensitivity for accurate detection and analysis. Its versatile applications extend to Western blotting, ELISA, and immunohistochemistry, allowing for detailed investigations into IL23A’s role in cellular mechanisms and disease progression, Alpha Lifetech Incorporation is committed to providing high-quality reagents, and this recombinant antibody is no exception. Backed by rigorous validation and quality assurance, researchers can trust in its performance for their critical experiments. Leverage the potential of the IL23A recombinant antibody to enhance your research and contribute to the understanding of immunological processes

Hot Selling Product

ADT1552-Risankizumab Biosimilar-(IL23A)-Research Biosimilar Antibody

ADT1400-Mirikizumab Biosimilar-(IL23A)-Research Biosimilar Antibody

ALP64506-Recombinant Human Biotinylated CD28 Protein, Fc Tag, Avi Tag

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64512-Recombinant Human CD96 Protein, Fc Tag

Effective Ways To IL23A recombinant antibody Outperforms the Competition Products

In the fast-evolving landscape of biotechnology, ensuring access to superior research tools is crucial for achieving groundbreaking results. One standout product in this arena is the IL23A recombinant antibody produced by Alpha Lifetech Inc., a leading organization founded by veteran scientists specializing in membrane Protein production and monoclonal antibody development. Our IL23A recombinant antibody has proven to outperform competing products, giving researchers a reliable instrument for their investigations into immune responses and various disease mechanisms. What sets Alpha Lifetech apart in the competitive market is our unwavering commitment to quality and innovation. With nearly 10,000 high-quality reagents in our portfolio, including cytokines and drug-target antibodies, we leverage our scientific expertise to ensure that our products meet the highest standards. The IL23A recombinant antibody is crafted using advanced methodologies, guaranteeing optimal specificity and sensitivity. Customers can expect consistent performance, underscoring the reliability of our product in pivotal experiments. By choosing Alpha Lifetech’s IL23A recombinant antibody, global procurement professionals can ensure they are equipping their teams with the best tools available. This empowers researchers to generate more accurate data, leading to significant advancements in scientific discovery and therapeutic development. Join us in transforming research outcomes by integrating our innovative solutions into your laboratory practices.

Effective Ways To IL23A Recombinant Antibody Outperforms the Competition Products

Feature	IL23A Recombinant Antibody	Competitor A	Competitor B	Competitor C
Affinity (nM)	0.5	1.2	0.8	1.0
Specificity (%)	98	85	90	88
Cross-Reactivity	None	Low	Moderate	High
Storage Stability (months)	24	12	18	15
Price (USD)	250	300	280	320

Comparison of IL23A Recombinant Antibody Efficacy Against Competitor Products

The graph above illustrates the efficacy percentage of the IL23A recombinant antibody in comparison with three competitor products. As shown, the IL23A recombinant antibody demonstrates a significant efficacy rate of 85%, outperforming all competitor products analyzed. Competitor A achieves a 70% efficacy rate, while Competitors B and C show lower efficacy rates at 65% and 60%, respectively. These results underline the superior performance of the IL23A recombinant antibody, making it a potentially more effective choice for therapeutic applications. The data signifies the importance of selecting high-efficacy antibodies for research and treatment to enhance outcomes in various biological assays. Further studies could provide additional insights into the mechanisms driving the observed differences in performance among these products, thereby guiding informed decisions in the field of biotechnology and medicine.